SHANGHAI, March 19 (Reuters) - AstraZeneca said on Thursday it will build a cell therapy manufacturing and supply base and an ...

British pharma major AstraZeneca (LSE: AZN) is stepping up its China strategy with plans to build a commercial cell therapy manufacturing and supply base in Shanghai, alongside a new innovation center ...

The EU approval of Imfinzi for early-stage gastric and gastroesophageal cancers expands the label of one of the company’s top ...

The company is establishing commercial production capabilities to fuel plans to launch autologous CAR-T cell therapies in China.

Multinationals are building self-reliant supply chains in China to insulate local markets from potential trade disruptions, ...

Following through with its sizable investment commitment in China, AstraZeneca on Thursday unveiled plans to build a commercial cell therapy manufacturing base and an innovation center dedicated to | ...

French biotech Abivax has been the subject of intense takeover speculation for months. But a spokesperson denied a report by La Lettre that AstraZeneca was ...

The planned Shanghai facility extends a yearslong push into the field and will support CAR-T therapies AstraZeneca is making for autoimmune disease and cancer.

The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...

AstraZeneca, a global, science-led biopharmaceutical company, has made available its treatment, Soliris®, in Malaysia as part of its ongoing ...

AstraZeneca said on Thursday it would build a cell therapy ​manufacturing and supply base and an innovation centre ‌in ...

By Sabrina Valle NEW YORK, March 12 (Reuters) - Biotechnology company Abivax on Thursday dismissed a report by French media ...